0001193125-16-454772.txt : 20160209 0001193125-16-454772.hdr.sgml : 20160209 20160209085552 ACCESSION NUMBER: 0001193125-16-454772 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160209 DATE AS OF CHANGE: 20160209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERIDIAN BIOSCIENCE INC CENTRAL INDEX KEY: 0000794172 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 310888197 STATE OF INCORPORATION: OH FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-14902 FILM NUMBER: 161397426 BUSINESS ADDRESS: STREET 1: 3471 RIVER HILLS DR CITY: CINCINNATI STATE: OH ZIP: 45244 BUSINESS PHONE: 5132713700 MAIL ADDRESS: STREET 1: 3471 RIVER HILLS DRIVE CITY: CINCINNATI STATE: OH ZIP: 45244 FORMER COMPANY: FORMER CONFORMED NAME: MERIDIAN DIAGNOSTICS INC DATE OF NAME CHANGE: 19920703 10-Q 1 d51894d10q.htm QUARTERLY REPORT Quarterly Report
Table of Contents

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended December 31, 2015

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number 0-14902

 

 

MERIDIAN BIOSCIENCE, INC.

 

Incorporated under the laws of Ohio

 

 

31-0888197

 

(I.R.S. Employer Identification No.)

3471 River Hills Drive

Cincinnati, Ohio 45244

(513) 271-3700

Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   x    Accelerated filer   ¨
Non-accelerated filer   ¨    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class

       

Outstanding January 31, 2016

Common Stock, no par value         42,051,142

 

 

 


Table of Contents

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

TABLE OF CONTENTS TO QUARTERLY REPORT ON FORM 10-Q

 

   

 

       Page(s)  
PART I.  

FINANCIAL INFORMATION

  

Item 1.

  Financial Statements (Unaudited)   
   

Condensed Consolidated Statements of Operations
Three Months Ended December 31, 2015 and 2014

     1   
   

Condensed Consolidated Statements of Comprehensive Income
Three Months Ended December 31, 2015 and 2014

     2   
   

Condensed Consolidated Statements of Cash Flows
Three Months Ended December 31, 2015 and 2014

     3   
   

Condensed Consolidated Balance Sheets
December 31, 2015 and September 30, 2015

     4-5   
   

Condensed Consolidated Statement of Changes in Shareholders’ Equity
Three Months Ended December 31, 2015

     6   
   

Notes to Condensed Consolidated Financial Statements

     7-10   

Item 2.

  Management’s Discussion and Analysis of
Financial Condition and Results of Operations
     10-17   

Item 3.

  Quantitative and Qualitative Disclosures About Market Risk      17   

Item 4.

  Controls and Procedures      17   

PART II.

  OTHER INFORMATION   

Item 1A.

  Risk Factors      18   

Item 6.

  Exhibits      18   

Signature

         19   


Table of Contents

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Meridian relies on proprietary, patented and licensed technologies, and the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.


Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)

 

     Three Months Ended  
     December 31,  
     2015      2014  

NET REVENUES

   $ 47,160      $ 48,013  

COST OF SALES

     15,577        18,776  
  

 

 

    

 

 

 

GROSS PROFIT

     31,583        29,237  
  

 

 

    

 

 

 

OPERATING EXPENSES

     

Research and development

     3,381        3,103  

Selling and marketing

     6,443        6,080  

General and administrative

     8,173        7,385  
  

 

 

    

 

 

 

Total operating expenses

     17,997        16,568  
  

 

 

    

 

 

 

OPERATING INCOME

     13,586        12,669  

OTHER INCOME (EXPENSE)

     

Interest income

     17        6  

Other, net

     96        (582
  

 

 

    

 

 

 

Total other income (expense)

     113        (576
  

 

 

    

 

 

 

EARNINGS BEFORE INCOME TAXES

     13,699        12,093  

INCOME TAX PROVISION

     4,806        4,192  
  

 

 

    

 

 

 

NET EARNINGS

   $ 8,893      $ 7,901  
  

 

 

    

 

 

 

BASIC EARNINGS PER COMMON SHARE

   $ 0.21      $ 0.19  

DILUTED EARNINGS PER COMMON SHARE

   $ 0.21      $ 0.19  

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING—BASIC

     41,947        41,607  

EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARES AND UNITS

     380        334  
  

 

 

    

 

 

 

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING—DILUTED

     42,327        41,941  
  

 

 

    

 

 

 

ANTI-DILUTIVE SECURITIES:

     

Common share options and restricted shares and units

     450        566  
  

 

 

    

 

 

 

DIVIDENDS DECLARED PER COMMON SHARE

   $ 0.20      $ 0.20  
  

 

 

    

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

Page 1


Table of Contents

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(in thousands)

 

     Three Months
Ended
 
     December 31,  
     2015     2014  

NET EARNINGS

   $ 8,893     $ 7,901  

Foreign currency translation adjustment

     (787     (1,365
  

 

 

   

 

 

 

COMPREHENSIVE INCOME

   $ 8,106     $ 6,536  
  

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

Page 2


Table of Contents

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

 

Three Months Ended December 31,

   2015     2014  

CASH FLOWS FROM OPERATING ACTIVITIES

    

Net earnings

   $ 8,893     $ 7,901  

Non-cash items included in net earnings:

    

Depreciation of property, plant and equipment

     896       927  

Amortization of intangible assets

     388       469  

Amortization of deferred illumigene® instrument costs

     281       395  

Stock-based compensation

     1,611       1,428  

Deferred income taxes

     433       100  

Change in current assets

     (1,186     4,878  

Change in current liabilities

     834       246  

Other, net

     (58     (259
  

 

 

   

 

 

 

Net cash provided by operating activities

     12,092       16,085  
  

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

    

Purchases of property, plant and equipment

     (776     (1,331

Purchase of equity method investment

     (600     —    

Purchases of intangible assets

     (16     —    
  

 

 

   

 

 

 

Net cash used for investing activities

     (1,392     (1,331
  

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

    

Dividends paid

     (8,407     (8,330

Proceeds and tax benefits from exercises of stock options

     1,470       499  
  

 

 

   

 

 

 

Net cash used for financing activities

     (6,937     (7,831
  

 

 

   

 

 

 

Effect of Exchange Rate Changes on Cash and Equivalents

     (314     (454
  

 

 

   

 

 

 

Net Increase in Cash and Equivalents

     3,449       6,469  

Cash and Equivalents at Beginning of Period

     49,973       43,047  
  

 

 

   

 

 

 

Cash and Equivalents at End of Period

   $ 53,422     $ 49,516  
  

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

Page 3


Table of Contents

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands)

ASSETS

 

     December 31,
2015
     September 30,
2015
 
     (Unaudited)         

CURRENT ASSETS

     

Cash and equivalents

   $ 53,422      $ 49,973  

Accounts receivable, less allowances of $222 and $248

     27,617        26,254  

Inventories

     38,778        35,817  

Prepaid expenses and other current assets

     3,414        7,378  
  

 

 

    

 

 

 

Total current assets

     123,231        119,422  
  

 

 

    

 

 

 

PROPERTY, PLANT AND EQUIPMENT, at Cost

     

Land

     981        986  

Buildings and improvements

     30,119        30,056  

Machinery, equipment and furniture

     42,363        41,541  

Construction in progress

     938        1,139  
  

 

 

    

 

 

 

Subtotal

     74,401        73,722  

Less: accumulated depreciation and amortization

     46,952        46,230  
  

 

 

    

 

 

 

Net property, plant and equipment

     27,449        27,492  
  

 

 

    

 

 

 

OTHER ASSETS

     

Goodwill

     22,064        22,349  

Other intangible assets, net

     5,465        5,931  

Restricted cash

     1,000        1,000  

Deferred illumigene instrument costs, net

     1,671        1,750  

Deferred income taxes

     4,566        4,954  

Other assets

     989        384  
  

 

 

    

 

 

 

Total other assets

     35,755        36,368  
  

 

 

    

 

 

 

TOTAL ASSETS

   $ 186,435      $ 183,282  
  

 

 

    

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

Page 4


Table of Contents

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(dollars in thousands)

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

     December 31,
2015
    September 30,
2015
 
     (Unaudited)        

CURRENT LIABILITIES

    

Accounts payable

   $ 7,208     $ 6,646  

Accrued employee compensation costs

     4,990       5,132  

Other accrued expenses

     2,601       2,587  

Income taxes payable

     933       886  
  

 

 

   

 

 

 

Total current liabilities

     15,732       15,251  
  

 

 

   

 

 

 

NON-CURRENT LIABILITIES

     2,129       2,158  

COMMITMENTS AND CONTINGENCIES

    

SHAREHOLDERS’ EQUITY

    

Preferred stock, no par value; 1,000,000 shares authorized; none issued

     —         —    

Common shares, no par value; 71,000,000 shares authorized; 42,044,388 and 41,838,399 shares issued, respectively

     —         —    

Additional paid-in capital

     120,153       117,151  

Retained earnings

     51,538       51,052  

Accumulated other comprehensive income (loss)

     (3,117     (2,330
  

 

 

   

 

 

 

Total shareholders’ equity

     168,574       165,873  
  

 

 

   

 

 

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

   $ 186,435     $ 183,282  
  

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

Page 5


Table of Contents

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statement of Changes in Shareholders’ Equity (Unaudited)

(dollars and shares in thousands)

 

     Common
Shares
Issued
     Additional
Paid-In
Capital
     Retained
Earnings
    Accumulated
Other
Comprehensive
Income (Loss)
    Total
Shareholders’
Equity
 

Balance at September 30, 2015

     41,838      $ 117,151      $ 51,052     $ (2,330   $ 165,873  

Cash dividends paid

     —          —          (8,407     —         (8,407

Exercise of stock options

     91        1,391        —         —         1,391  

Conversion of restricted stock units

     115        —          —         —         —    

Stock compensation expense

     —          1,611        —         —         1,611  

Net earnings

     —          —          8,893       —         8,893  

Foreign currency translation adjustment

     —          —          —         (787     (787
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at December 31, 2015

     42,044      $ 120,153      $ 51,538     $ (3,117   $ 168,574  
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

Page 6


Table of Contents

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Dollars in Thousands, Except Per Share Amounts

(Unaudited)

1. Basis of Presentation

The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of December 31, 2015, the results of its operations for the three month periods ended December 31, 2015 and 2014, and its cash flows for the three month periods ended December 31, 2015 and 2014. These statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s fiscal 2015 Annual Report on Form 10-K. Financial information as of September 30, 2015 has been derived from the Company’s audited consolidated financial statements. The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

2. Significant Accounting Policies

A summary of the Company’s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company’s fiscal 2015 Annual Report on Form 10-K.

 

(a) Recent Accounting Pronouncements

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which simplifies the financial statement presentation of deferred income taxes by requiring that deferred income tax assets and liabilities be classified as noncurrent within a classified statement of financial position. Adoption and implementation of the guidance is not required by the Company until issuance of fiscal 2018 first quarter financial statements. However, in light of early adoption being permitted and believing the required presentation results in more useful and comparable information related to our net deferred income tax assets, the Company has chosen to adopt the guidance as of December 31, 2015 and retrospectively apply the guidance to the prior period presented. This retrospective application results in $3,431 of deferred income tax assets being reclassified from current assets to non-current assets in the September 30, 2015 balance sheet included herein. Adoption of this guidance did not have an impact on the Company’s consolidated results of operations or cash flows.

Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Condensed Consolidated Financial Statements.

 

(b) Reclassifications

Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

 

Page 7


Table of Contents

3. Cash and Equivalents

Cash and equivalents include the following components:

 

     December 31, 2015      September 30, 2015  
     Cash and
Equivalents
     Other
Assets
     Cash and
Equivalents
     Other
Assets
 

Overnight repurchase agreements

   $ 25,147      $ —        $ 25,436      $ —    

Cash on hand—

           

Restricted

     —          1,000        —          1,000  

Unrestricted

     28,275        —          24,537        —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 53,422      $ 1,000      $ 49,973      $ 1,000  
  

 

 

    

 

 

    

 

 

    

 

 

 

4. Inventories

Inventories are comprised of the following:

 

     December 31,
2015
     September 30,
2015
 

Raw materials

   $ 7,351      $ 7,095  

Work-in-process

     12,297        10,096  

Finished goods—illumigene instruments

     2,260        1,890  

Finished goods—kits and reagents

     16,870        16,736  
  

 

 

    

 

 

 

Total

   $ 38,778      $ 35,817  
  

 

 

    

 

 

 

5. Reportable Segment and Major Customers Information

Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Our reportable segments are Diagnostics and Life Science, both of which are headquartered in Cincinnati, Ohio, which also serves as the Diagnostics segment’s base of manufacturing operations and research and development. The Diagnostics segment has sales and distribution facilities in the United States, Europe and Australia. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China to further pursue growing revenue opportunities in Asia.

Amounts due from two Diagnostics distributor customers accounted for 26% and 21% of consolidated accounts receivable at December 31, 2015 and September 30, 2015, respectively. Revenues from these two distributor customers accounted for 39% and 41% of the Diagnostics segment third-party revenues during the three months ended December 31, 2015 and 2014, respectively; and represented 29% and 31% of consolidated revenues for the fiscal 2016 and 2015 first quarters, respectively.

 

Page 8


Table of Contents

Within our Life Science segment, two diagnostic manufacturing customers accounted for 18% of the segment’s third-party revenues during each of the three months ended December 31, 2015 and 2014.

Segment information for the interim periods is as follows:

 

     Diagnostics      Life Science      Eliminations(1)      Total  

Three Months Ended December 31, 2015

  

Net revenues—

           

Third-party

   $ 35,301      $ 11,859      $ —        $ 47,160  

Inter-segment

     71        367        (438      —    

Operating income

     10,330        3,236        20        13,586  

Goodwill (December 31, 2015)

     1,250        20,814        —          22,064  

Other intangible assets, net (December 31, 2015)

     2,236        3,229        —          5,465  

Total assets (December 31, 2015)

     120,780        65,927        (272      186,435  

Three Months Ended December 31, 2014

           

Net revenues—

           

Third-party

   $ 36,586      $ 11,427      $ —        $ 48,013  

Inter-segment

     104        297        (401      —    

Operating income

     10,284        2,489        (104      12,669  

Goodwill (September 30, 2015)

     1,250        21,099        —          22,349  

Other intangible assets, net (September 30, 2015)

     2,364        3,567        —          5,931  

Total assets (September 30, 2015)

     119,939        63,670        (327      183,282  

 

(1) Eliminations consist of inter-segment transactions.

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

6. Intangible Assets

A summary of our acquired intangible assets subject to amortization, as of December 31, 2015 and September 30, 2015 is as follows:

 

     December 31, 2015      September 30, 2015  
     Gross
Carrying
Value
     Accumulated
Amortization
     Gross
Carrying
Value
     Accumulated
Amortization
 

Manufacturing technologies, core products and cell lines

   $ 11,547      $ 10,963      $ 11,582      $ 10,906  

Trademarks, licenses and patents

     6,349        3,450        6,410        3,296  

Customer lists and supply agreements

     12,012        10,030        12,105        9,964  
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 29,908      $ 24,443      $ 30,097      $ 24,166  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

Page 9


Table of Contents

The actual aggregate amortization expense for these intangible assets was $388 and $469 for the three months ended December 31, 2015 and 2014, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2021 is as follows: remainder of fiscal 2016 – $1,009, fiscal 2017 – $1,106, fiscal 2018 – $1,085, fiscal 2019 – $1,045, fiscal 2020 – $873 and fiscal 2021 – $313.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Refer to “Forward-Looking Statements” following the Table of Contents in front of this Form 10-Q. In the discussion that follows, all dollar amounts are in thousands (both tables and text), except per share data.

Following is a discussion and analysis of the financial statements and other statistical data that management believes will enhance the understanding of Meridian’s financial condition, changes in financial condition and results of operations. This discussion should be read in conjunction with the financial statements and notes thereto beginning on page 1.

Results of Operations

Net earnings for the first quarter of fiscal 2016 increased 13% to $8,893, or $0.21 per diluted share, from net earnings for the first quarter of fiscal 2015 of $7,901, or $0.19 per diluted share. Consolidated revenues decreased 2% to $47,160 for the first quarter of fiscal 2016 compared to the same period of the prior year and were flat on a constant-currency basis.

Included within the first quarter of fiscal 2016 were revenues from our illumigene® molecular platform of products totaling $9,836, representing a 1% decrease from the fiscal 2015 first quarter (flat on a constant-currency basis). Also contributing to the consolidated revenues decrease were decreased revenues in three of our diagnostic focus product families (C. difficile, foodborne and respiratory) and our Life Science segment’s molecular component business line. Serving to substantially offset these decreases were increased revenues in our H. pylori and women’s health & STD focus product families and our Life Science segment’s immunoassay components business.

Revenues for the Diagnostics segment for the first quarter of fiscal 2016 decreased 4% compared to the first quarter of fiscal 2015 (decreased 2% on a constant-currency basis), reflecting the following for each of our focus product families: 2% decline in our C. difficile products, 9% decline in our respiratory products, 11% decline in our foodborne products, 7% growth in our women’s health & STD products, and 19% growth in our H. pylori products. With growth in its immunoassay component business and a decline in its molecular components business, revenues of our Life Science segment increased by 4% during the first quarter of fiscal 2016 compared to the first quarter of fiscal 2015, increasing 6% on a constant-currency basis.

Additionally, during November 2015, we made a minority investment in Oasis Diagnostics® Corporation (“Oasis”), with the right to acquire 100% ownership interest in the future. Located in Vancouver, Washington, Oasis designs, develops, manufactures and sells pre-analytic tools for the collection, preservation, and transportation of saliva/oral fluids – and our investment was made to explore our interest in saliva diagnostics and collection devices. Our investment in Oasis has been accounted for as an equity method investment and is included within other assets in the accompanying Condensed Consolidated Balance Sheet as of December 31, 2015.

 

Page 10


Table of Contents

REVENUE OVERVIEW

Below are analyses of the Company’s revenue, provided for each of the following:

- By Reportable Segment & Geographic Region

- By Product Platform/Type

- By Disease Family (Diagnostics only)

Revenue Overview- By Reportable Segment & Geographic Region

Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the countries comprising North, Central and South America (the “Americas”); Europe, Middle East and Africa (“EMEA”); and other countries outside of the Americas and EMEA (rest of the world, or “ROW”). The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China to further pursue growing revenue opportunities in Asia.

Revenues for the Diagnostics segment, in the normal course of business, may be affected from quarter to quarter by buying patterns of major distributors, seasonality and strength of certain diseases, and foreign currency exchange rates. Revenues for the Life Science segment, in the normal course of business, may be affected from quarter to quarter by buying patterns of major customers and foreign currency exchange rates. We believe that the overall breadth of our product lines serves to reduce the variability in consolidated revenues due to these factors.

 

     Three Months Ended December 31,  
     2015     2014     Inc (Dec)  

Diagnostics-

      

Americas

   $ 30,115     $ 30,913       (3 )% 

EMEA

     4,649       5,003       (7 )% 

ROW

     537       670       (20 )% 
  

 

 

   

 

 

   

 

 

 

Total Diagnostics

     35,301       36,586       (4 )% 
  

 

 

   

 

 

   

 

 

 

Life Science-

      

Americas

     5,103       5,299       (4 )% 

EMEA

     4,536       3,758       21 

ROW

     2,220       2,370       (6 )% 
  

 

 

   

 

 

   

 

 

 

Total Life Science

     11,859       11,427      
  

 

 

   

 

 

   

 

 

 

Consolidated

   $ 47,160     $ 48,013       (2 )% 
  

 

 

   

 

 

   

 

 

 

% of total revenues-

      

Diagnostics

     75      76   

Life Science

     25      24   
  

 

 

   

 

 

   

Total

     100      100   
  

 

 

   

 

 

   

Ex-Americas

     25      25   
  

 

 

   

 

 

   

 

Page 11


Table of Contents

Revenue Overview- By Product Platform/Type

The revenues generated by each of our reportable segments result primarily from the sale of the following segment-specific categories of products:

Diagnostics

1) Molecular tests that operate on our illumigene platform

2) Immunoassay tests on multiple technology platforms

Life Science

1) Molecular components

2) Immunoassay components

Revenues for each product platform/type, as well as its relative percentage of segment revenue, are shown below.

 

     Three Months Ended December 31,  
     2015     2014     Inc (Dec)  

Diagnostics-

      

Molecular

   $ 9,836     $ 9,908       (1 )% 

Immunoassay

     25,465       26,678       (5 )% 
  

 

 

   

 

 

   

 

 

 

Total Diagnostics

   $ 35,301     $ 36,586       (4 )% 
  

 

 

   

 

 

   

 

 

 

Life Science-

      

Molecular components

   $ 4,749     $ 5,012       (5 )% 

Immunoassay components

     7,110       6,415       11 
  

 

 

   

 

 

   

 

 

 

Total Life Science

   $ 11,859     $ 11,427      
  

 

 

   

 

 

   

 

 

 

% of Diagnostics revenues-

      

Molecular

     28      27   

Immunoassay

     72      73   
  

 

 

   

 

 

   

Total Diagnostics

     100      100   
  

 

 

   

 

 

   

% of Life Science revenues-

      

Molecular components

     40      44   

Immunoassay components

     60      56   
  

 

 

   

 

 

   

Total Life Science

     100      100   
  

 

 

   

 

 

   

Following is a discussion of the revenues generated by each of these product platforms/types:

Diagnostics Products

illumigene Molecular Platform Products

We have approximately 1,490 customer account placements. Of these account placements, over 1,300 accounts have completed evaluations and validations and are regularly purchasing product, with the balance of our account placements being in some stage of product evaluation and/or validation. Of our account placements, we have over 400 accounts that are regularly purchasing, evaluating and/or validating two or more assays.

We continue to invest in new product development for our molecular testing platform, illumigene. This platform now has the following commercialized tests:

1. illumigene® C. difficile – commercialized in August 2010

2. illumigene® Group B Streptococcus (Group B Strep or GBS) – commercialized in December 2011

3. illumigene® Group A Streptococcus (Group A Strep) – commercialized in September 2012

4. illumigene® Mycoplasma (M. pneumonia; walking pneumonia) – commercialized in June 2013

 

Page 12


Table of Contents

5. illumigene® Bordetella pertussis (whooping cough) – commercialized in March 2014

6. illumigene® Chlamydia trachomatis – commercialized outside of U.S. in February 2015

7. illumigene® Neisseria gonorrhea – commercialized outside of U.S. in February 2015

8. illumigene® HSV 1&2 (Herpes Simplex Virus Type 1 & Type 2) – commercialized outside of U.S. in May 2015; commercialized in U.S. in July 2015

9. illumigene® Malaria – commercialized outside of U.S. in February 2016

We have several additional illumigene tests in development and have a robust pipeline of illumigene opportunities. We continue to add new assays to our illumigene platform menu, with our latest being malaria, which was launched in the EMEA region in February 2016.

We believe that the diagnostic testing market is continuing to selectively move away from culture and immunoassay testing to molecular testing for diseases where there is a favorable cost/benefit position for the total cost of health care. While this market is competitive, with molecular companies such as Cepheid and Becton Dickinson and others such as Quidel, Great Basin, Nanosphere, and Alere, we believe we are well positioned to capitalize on the migration to molecular testing. Our simple, easy-to-use, illumigene platform, with its expanding menu, requires no expensive equipment purchase and little to no maintenance cost. We believe these features, along with its small footprint and the performance of the illumigene assays, make illumigene an attractive molecular platform to any size hospital or physician office laboratory that runs moderately-complex tests.

Immunoassay Products

Revenues from our Diagnostics segment’s immunoassay products decreased 5% in the first quarter of fiscal 2016. As described in the product discussions below, the current year decrease results primarily from the decline in revenues of our foodborne, C. difficile and respiratory immunoassay products, partially offset by the revenue increase in our H. pylori products.

Life Science Products

During the first quarter of fiscal 2016, revenues from our Life Science segment increased 4%, with revenues from molecular component sales decreasing 5% from the comparable fiscal 2015 quarter and revenues from immunoassay component sales increasing 11%. Our molecular component business’ growth was negatively impacted by the movement in currency exchange rates since the fiscal 2015 first quarter, with the revenues increasing less than 1% on a constant-currency basis over the fiscal 2015 first quarter. Our Life Science segment continued to benefit from increased sales into China, with such sales totaling approximately $500 during the fiscal 2016 first quarter (primarily in the immunoassay components business).

Diagnostics Revenue Overview- By Disease Family

Revenues from our focus families (C. difficile, foodborne, H. pylori, respiratory and women’s health & STD) comprised 81% and 78% of our Diagnostics segment’s revenues during the first quarter of fiscal 2016 and 2015, respectively. Following is a discussion of the revenues generated by each product family:

C. difficile Products

During the fiscal 2016 first quarter, revenues for our C. difficile product family decreased 2% to $7,400 from the first quarter of fiscal 2015 (flat in constant-currency). Our molecular products now represent over 80% of this product category. The C. difficile test market continues to be highly competitive, with over 10 suppliers in the United States, certain of which choose to compete solely on price. During the first quarter of fiscal 2016, the amount and rate of decline in constant-currency revenues has continued to decrease. We believe this is due largely to the expansion of our illumigene molecular platform menu having a positive effect on defending our C. difficile business.

Foodborne Products

Revenues from our foodborne products (Enterohemorrhagic E. coli (EHEC) and Campylobacter), all of which are immunoassay products, totaled $5,300 during the first quarter of fiscal 2016, an 11% decrease from the fiscal 2015 first quarter (also 11% in constant-currency). Revenues for our foodborne products during the first quarter of fiscal 2016 were affected by distributor ordering patterns. We are continuing to re-emphasize the benefits of increased sensitivity and faster turnaround time versus culture methods in our marketing programs. The primary competition

 

Page 13


Table of Contents

for our foodborne products is laboratory culture methods and an immunoassay EHEC shiga toxin test from one of our competitors. We believe that our test offers better workflow, less hands-on time and quicker results, in addition to being fully compliant with CDC-recommended testing methods. More recently, multi-plex gastro-intestinal panels are introducing new competition in this product category.

H. pylori Products

During the fiscal 2016 first quarter, revenues from our H. pylori products, all of which are immunoassay products, increased 19% (22% in constant-currency) to $8,700. This increase continues to reflect the benefits of our partnerships with managed care companies in promoting (i) the health and economic benefits of a test and treat strategy; (ii) changes in policies that discourage the use of traditional serology methods and promote the utilization of active infection testing methods; and (iii) physician behavior movement away from serology-based testing and toward direct antigen testing. A significant amount of the H. pylori product revenues are sales to reference labs, whose buying patterns may not be consistent from period to period. In addition to our managed care strategy, we have also begun to increase sales promotions into selected distribution and laboratory channels as a defensive strategy against potential new competitive product introductions later in the year.

The patents for our H. pylori products are owned by us and expire in May 2016 in the U.S. and in 2017 in countries outside the U.S. We expect competition with respect to our H. pylori products to increase upon the expiration of these patents in 2016 and 2017 as we currently market the only FDA-cleared test to detect H. pylori antigen in stool samples. Such competition may have an adverse impact on our selling prices for these products, or our ability to retain business at prices acceptable to us, and consequently, adversely affect our future results of operations and liquidity, including revenues and gross profit. In order to mitigate any loss in revenues upon patent expiration, among other things, we are researching and experimenting with new products (e.g., detection of H. pylori on molecular platforms) and attempting to secure significant customers under long-term contracts. We are unable to provide any assurances that we will be successful with any mitigation strategy or that any mitigation strategy will prevent an adverse effect on our future results of operations and liquidity, including revenues and gross profit.

Respiratory Products

Total respiratory revenues for our Diagnostics segment decreased 9% to $5,600 during the first quarter of fiscal 2016 (decreased 8% in constant-currency). This decline was largely due to the success of promotional “stock-and-block” programs in the third (influenza) and fourth (Group A strep) quarters of fiscal 2015 that affected buying patterns in the first quarter of fiscal 2016.

Women’s Health & STD Products

Revenues from our women’s health & STD products, all of which are molecular products, totaled $1,700 during the first quarter of fiscal 2016, a 7% increase from the fiscal 2015 first quarter (also 7% in constant-currency). This growth primarily reflects the results of our commercialization during fiscal 2015 of three illumigene tests for sexually transmitted diseases (Chlamydia, Gonorrhea and HSV).

Significant Customers

Two U.S. distributors accounted for 39% and 41% of our Diagnostics segment’s total revenues for the first quarter of fiscal 2016 and 2015, respectively. These revenues represented 29% and 31% of consolidated revenues for the fiscal 2016 and 2015 first quarters, respectively.

Within our Life Science segment, two diagnostic manufacturing customers accounted for 18% of the segment’s total revenues for each of the first quarters of fiscal 2016 and 2015.

Medical Device Tax

On January 1, 2013, the medical device tax established as part of the U.S. health care reform legislation became effective, and as a result, the Company made its first required tax deposit near the end of January 2013. During each of the first quarters of fiscal 2016 and fiscal 2015, the Company recorded approximately $500 of medical device tax expense, which is reflected as a component of cost of sales in the accompanying Condensed Consolidated

 

Page 14


Table of Contents

Statements of Operations. During December 2015, the Consolidations Appropriations Act of 2016 imposed a two-year moratorium on this excise tax effective January 1, 2016. During calendar years 2016 and 2017, this moratorium would result in approximately $2,000 of savings each year. We are unable to predict any future legislative changes or developments related to this moratorium or excise tax.

Gross Profit

 

     Three Months Ended December 31,  
     2015     2014     Change  

Gross Profit

   $ 31,583     $ 29,237      

Gross Profit Margin

     67      61      +6 points   

The overall gross profit increase for the three months ended December 31, 2015 primarily results from the combined effects of (i) mix of products sold, particularly the higher revenue contribution from H. pylori products; (ii) realization of manufacturing facility efficiencies for our illumigene products as a result of bringing in-house certain reagent dispensing operations that were previously outsourced; (iii) manufacturing efficiencies in our Life Science segment; and (iv) favorable effects of currency rates related to products where the purchase cost is denominated in Euros but the customer sales are billed in U.S. dollars.

Our overall operations consist of the sale of diagnostic test kits for various disease states and in alternative test formats, as well as bioresearch reagents, bulk antigens and antibodies, PCR/qPCR reagents, nucleotides, competent cells, proficiency panels, and contract manufacturing services. Product revenue mix shifts, in the normal course of business, can cause the consolidated gross profit margin to fluctuate by several points.

Operating Expenses

 

     Changes for the Three Months Ended December 31, 2015  
     Research &
Development
    Selling &
Marketing
    General &
Administrative
    Total
Operating
Expenses
 

2015 Expenses

   $ 3,103     $ 6,080     $ 7,385     $ 16,568  
  

 

 

   

 

 

   

 

 

   

 

 

 

% of Revenues

         13      15      35 

Fiscal 2016 Increases (Decreases):

        

Diagnostics

     395       29       693       1,117  

Life Science

     (117     334       95       312  
  

 

 

   

 

 

   

 

 

   

 

 

 

2016 Expenses

   $ 3,381     $ 6,443     $ 8,173     $ 17,997  
  

 

 

   

 

 

   

 

 

   

 

 

 

% of Revenues

         14      17      38 

% Increase

             11     

Total operating expenses increased during the first quarter of fiscal 2016 compared to the first quarter of fiscal 2015. This level of operating expenses results primarily from the combined effects of our (i) ongoing efforts to control spending in each of our segments while investing the necessary resources in our strategic areas of growth, including increased investment in new product development in our Diagnostics segment, and increased investment in Sales and Marketing personnel and programs, particularly in our Life Science segment; and (ii) favorable effects of currency rates.

 

Page 15


Table of Contents

Operating expenses for the Diagnostics segment increased $1,117 for the first quarter of fiscal 2016 compared to the first quarter of fiscal 2015. These overall Diagnostics segment increases result primarily from the combined effects of the following:

Research & Development

Increase in spending on new product development activities, related primarily to the previously noted products for our illumigene molecular platform, as well as immunoassay products in development.

General & Administrative

Increase in incentive bonus and stock-based compensation expense as a result of the increase in corporate-wide operating profits, along with expenses incurred in connection with completing the Company’s investment in Oasis.

Operating Income

Operating income increased 7% to $13,586 for the first quarter of fiscal 2016, as a result of the factors discussed above.

Other Income and Expense

First quarter of fiscal 2016 other income and expense included approximately $100 of foreign currency gains. This compares to $600 of foreign currency losses in the first quarter of fiscal 2015, which related primarily to foreign currency exchange transaction losses on a subsidiary intercompany loan.

Income Taxes

The effective rate for income taxes remained stable at 35% for the first quarters of fiscal 2016 and fiscal 2015. For the fiscal year ending September 30, 2016, we expect the effective tax rate to approximate 34%-35%.

Liquidity and Capital Resources

Comparative Cash Flow Analysis

Our cash flow and financing requirements are determined by analyses of operating and capital spending budgets, consideration of acquisition plans, and consideration of common share dividends. We have historically maintained a credit facility to augment working capital requirements and to respond quickly to acquisition opportunities.

We have an investment policy that guides the holdings of our investment portfolio, which at present consist of overnight repurchase agreements and bank savings accounts. Our objectives are to (i) preserve capital; (ii) provide sufficient liquidity to meet working capital requirements and fund strategic objectives such as acquisitions; and (iii) capture a market rate of return commensurate with market conditions and our policy’s investment eligibility criteria. As we look forward, we will continue to manage the holdings of our investment portfolio with preservation of capital being the primary objective.

We do not expect economic conditions to have a significant impact on our liquidity needs, financial condition, or results of operations, although no assurances can be made in this regard. We intend to continue to fund our working capital requirements and dividends from current cash flows from operating activities and cash on hand. If needed, we also have an additional source of liquidity through our $30,000 bank credit facility. Our liquidity needs may change if overall economic conditions change and/or liquidity and credit within the financial markets tightens for an extended period of time, and such conditions impact the collectibility of our customer accounts receivable or impact credit terms with our vendors, or disrupt the supply of raw materials and services.

Net cash provided by operating activities totaled $12,092 for the first quarter of fiscal 2016, a 25% decrease from the $16,085 provided during the first quarter of fiscal 2015. While reflecting the effects of the timing of payments from and to customers and suppliers, respectively, this decrease reflects the approximate $3,000 increase in inventory during the quarter ended December 31, 2015, compared to the approximate $1,100 decrease in inventory during the quarter ended December 31, 2014. Net cash flows from operating activities and cash on hand are anticipated to be adequate to fund working capital requirements, capital expenditures and dividends during the next 12 months.

 

Page 16


Table of Contents

Capital Resources

We have a $30,000 credit facility with a commercial bank that expires on April 21, 2018. As of January 31, 2016, there were no borrowings outstanding on this facility and we had 100% borrowing capacity available to us. We have had no borrowings outstanding under this facility during the first three months of fiscal 2016 or during the full year of fiscal 2015.

Our capital expenditures are estimated to range between approximately $3,000 to $4,000 for fiscal 2016, with the actual amount depending upon actual operating results and the phasing of certain projects. Such expenditures may be funded with cash and equivalents on hand, operating cash flows, and/or availability under the $30,000 credit facility discussed above.

We do not utilize any special-purpose financing vehicles or have any undisclosed off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in the Company’s exposure to market risk since September 30, 2015.

ITEM 4. CONTROLS AND PROCEDURES

As of December 31, 2015, an evaluation was completed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) and 15d-15(b) promulgated under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective as of December 31, 2015. There have been no changes in our internal control over financial reporting identified in connection with the evaluation of internal control that occurred during the first fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, or in other factors that could materially affect internal control subsequent to December 31, 2015.

 

Page 17


Table of Contents

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS

There have been no material changes from risk factors as previously disclosed in the Registrant’s Form 10-K in response to Item 1A to Part I of Form 10-K.

 

ITEM 6. EXHIBITS
The following exhibits are being filed or furnished as a part of this Quarterly Report on Form 10-Q.
31.1    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)
31.2    Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)
32    Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101    The following financial information from Meridian Bioscience Inc.’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2015 filed with the SEC on February 9, 2016, formatted in XBRL includes: (i) Condensed Consolidated Statements of Operations for the three months ended December 31, 2015 and 2014; (ii) Condensed Consolidated Statements of Comprehensive Income for the three months ended December 31, 2015 and 2014; (iii) Condensed Consolidated Statements of Cash Flows for the three months ended December 31, 2015 and 2014; (iv) Condensed Consolidated Balance Sheets as of December 31, 2015 and September 30, 2015; (v) Condensed Consolidated Statement of Shareholders’ Equity for the three months ended December 31, 2015; and (vi) the Notes to Condensed Consolidated Financial Statements

 

Page 18


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    MERIDIAN BIOSCIENCE, INC.
Date: February 9, 2016     By:   /s/ Melissa A. Lueke
      Melissa A. Lueke
     

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

Page 19

EX-31.1 2 d51894dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)

I, John A. Kraeutler, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Meridian Bioscience, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 9, 2016

/s/ John A. Kraeutler

John A. Kraeutler

Chief Executive Officer

EX-31.2 3 d51894dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)

I, Melissa A. Lueke, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Meridian Bioscience, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 9, 2016

/s/ Melissa A. Lueke

Melissa A. Lueke

Executive Vice President and Chief Financial Officer

EX-32 4 d51894dex32.htm EX-32 EX-32

Exhibit 32

Meridian Bioscience, Inc.

Certification of Chief Executive Officer and Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the filing with the Securities and Exchange Commission of the Quarterly Report of Meridian Bioscience, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2015 (the “Report”), the undersigned officers of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ John A. Kraeutler

John A. Kraeutler

Chief Executive Officer

February 9, 2016

/s/ Melissa A. Lueke

Melissa A. Lueke

Executive Vice President and

Chief Financial Officer

February 9, 2016

EX-101.INS 5 vivo-20151231.xml XBRL INSTANCE DOCUMENT 42051142 49516000 71000000 1000000 0 42044388 2129000 120153000 4990000 168574000 24443000 933000 7208000 222000 2601000 51538000 186435000 0 46952000 15732000 -3117000 12297000 27617000 989000 186435000 1085000 1106000 5465000 38778000 1009000 27449000 1000000 313000 873000 123231000 981000 29908000 35755000 30119000 22064000 3414000 53422000 4566000 1045000 74401000 7351000 42363000 1671000 938000 10030000 12012000 10963000 11547000 3450000 6349000 16870000 2260000 28275000 25147000 53422000 1000000 1000000 120780000 2236000 1250000 65927000 3229000 20814000 -272000 42044000 51538000 120153000 -3117000 43047000 71000000 1000000 0 41838399 2158000 117151000 5132000 165873000 24166000 886000 6646000 248000 2587000 51052000 183282000 0 46230000 15251000 -2330000 10096000 26254000 384000 183282000 5931000 35817000 27492000 1000000 119422000 986000 30097000 36368000 30056000 22349000 7378000 49973000 4954000 73722000 7095000 41541000 1750000 1139000 9964000 12105000 10906000 11582000 3296000 6410000 16736000 1890000 3431000 24537000 25436000 49973000 1000000 1000000 119939000 2364000 1250000 63670000 3567000 21099000 -327000 41838000 51052000 117151000 -2330000 0.21 2 0.19 16085000 566000 334000 0.20 41941000 41607000 0.19 1331000 7901000 -4878000 48013000 8330000 12669000 29237000 -582000 -576000 6536000 12093000 -1365000 6000 259000 4192000 1428000 6080000 6469000 16568000 -1331000 -7831000 3103000 100000 -454000 7385000 469000 18776000 246000 927000 395000 499000 0.41 0.31 2 0.18 2 36586000 10284000 104000 11427000 2489000 297000 -401000 -104000 Q1 0.21 12092000 2016 false 450000 10-Q 0000794172 Large Accelerated Filer <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash and equivalents include the following components:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>September&#xA0;30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash and<br /> Equivalents</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Other<br /> Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash and<br /> Equivalents</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Other<br /> Assets</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Overnight repurchase agreements</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,147</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,436</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash on hand&#x2014;</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Restricted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Unrestricted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,275</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24,537</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,422</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,973</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> A summary of our acquired intangible assets subject to amortization, as of December&#xA0;31, 2015 and September&#xA0;30, 2015 is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>September&#xA0;30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br /> Carrying<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br /> Carrying<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Amortization</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Manufacturing technologies, core products and cell lines</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,547</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,963</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,582</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,906</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Trademarks, licenses and patents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,349</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,450</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,410</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,296</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Customer lists and supply agreements</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,012</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,030</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,105</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,964</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,908</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,443</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,097</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,166</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. <u>Basis of Presentation</u></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission.&#xA0;Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations.&#xA0;In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company&#x2019;s financial position as of December&#xA0;31, 2015, the results of its operations for the three month periods ended December&#xA0;31, 2015 and 2014, and its cash flows for the three month periods ended December&#xA0;31, 2015 and 2014. These statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company&#x2019;s fiscal 2015 Annual Report on Form 10-K.&#xA0;Financial information as of September&#xA0;30, 2015 has been derived from the Company&#x2019;s audited consolidated financial statements. The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>6. <u>Intangible Assets</u></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> A summary of our acquired intangible assets subject to amortization, as of December&#xA0;31, 2015 and September&#xA0;30, 2015 is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>September&#xA0;30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br /> Carrying<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br /> Carrying<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Amortization</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Manufacturing technologies, core products and cell lines</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,547</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,963</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,582</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,906</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Trademarks, licenses and patents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,349</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,450</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,410</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,296</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Customer lists and supply agreements</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,012</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,030</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,105</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,964</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,908</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,443</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,097</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,166</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> The actual aggregate amortization expense for these intangible assets was $388 and $469 for the three months ended December&#xA0;31, 2015 and 2014, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2021 is as follows: remainder of fiscal 2016 &#x2013; $1,009, fiscal 2017 &#x2013; $1,106, fiscal 2018 &#x2013; $1,085, fiscal 2019 &#x2013; $1,045, fiscal 2020 &#x2013; $873 and fiscal 2021 &#x2013; $313.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>5.&#xA0;<u>Reportable Segment and Major Customers Information</u></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i)&#xA0;the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; and (ii)&#xA0;the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Our reportable segments are Diagnostics and Life Science, both of which are headquartered in Cincinnati, Ohio, which also serves as the Diagnostics segment&#x2019;s base of manufacturing operations and research and development. The Diagnostics segment has sales and distribution facilities in the United States, Europe and Australia. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China to further pursue growing revenue opportunities in Asia.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Amounts due from two Diagnostics distributor customers accounted for 26% and 21% of consolidated accounts receivable at December&#xA0;31, 2015 and September&#xA0;30, 2015, respectively. Revenues from these two distributor customers accounted for 39% and 41% of the Diagnostics segment third-party revenues during the three months ended December&#xA0;31, 2015 and 2014, respectively; and represented 29% and 31% of consolidated revenues for the fiscal 2016 and 2015 first quarters, respectively.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Within our Life Science segment, two diagnostic manufacturing customers accounted for 18% of the segment&#x2019;s third-party revenues during each of the three months ended December&#xA0;31, 2015 and 2014.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Segment information for the interim periods is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Diagnostics</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Life&#xA0;Science</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> <b>Eliminations(1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top" colspan="16"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Three Months Ended December&#xA0;31, 2015</b></p> </td> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>&#xA0;&#xA0;</b></p> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net revenues&#x2014;</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Third-party</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,301</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,859</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,160</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Inter-segment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(438</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,330</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,236</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill (December 31, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,250</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,814</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,064</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other intangible assets, net (December 31, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,236</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,229</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,465</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total assets (December 31, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">120,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65,927</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(272</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">186,435</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Three Months Ended December&#xA0;31, 2014</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net revenues&#x2014;</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Third-party</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,427</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,013</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Inter-segment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">297</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(401</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,284</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,489</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(104</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,669</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill (September 30, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,250</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">21,099</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,349</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other intangible assets, net (September 30, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,364</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,567</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total assets (September 30, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">119,939</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63,670</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(327</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">183,282</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Eliminations consist of inter-segment transactions.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Inventories are comprised of the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,351</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,095</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Work-in-process</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,297</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,096</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Finished goods&#x2014;<b><i>illumi</i></b><i>gene</i> instruments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,260</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,890</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Finished goods&#x2014;kits and reagents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,870</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,736</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,778</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,817</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 380000 0.20 --09-30 MERIDIAN BIOSCIENCE INC <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>3. <u>Cash and Equivalents</u></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash and equivalents include the following components:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>September&#xA0;30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash and<br /> Equivalents</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Other<br /> Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash and<br /> Equivalents</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Other<br /> Assets</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Overnight repurchase agreements</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,147</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,436</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash on hand&#x2014;</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Restricted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Unrestricted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,275</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24,537</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,422</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,973</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>4. <u>Inventories</u></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Inventories are comprised of the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,351</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,095</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Work-in-process</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,297</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,096</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Finished goods&#x2014;<b><i>illumi</i></b><i>gene</i> instruments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,260</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,890</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Finished goods&#x2014;kits and reagents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,870</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,736</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,778</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,817</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 42327000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Segment information for the interim periods is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Diagnostics</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Life&#xA0;Science</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> <b>Eliminations(1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top" colspan="16"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Three Months Ended December&#xA0;31, 2015</b></p> </td> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>&#xA0;&#xA0;</b></p> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net revenues&#x2014;</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Third-party</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,301</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,859</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,160</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Inter-segment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(438</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,330</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,236</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill (December 31, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,250</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,814</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,064</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other intangible assets, net (December 31, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,236</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,229</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,465</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total assets (December 31, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">120,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65,927</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(272</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">186,435</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Three Months Ended December&#xA0;31, 2014</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net revenues&#x2014;</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Third-party</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,427</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,013</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Inter-segment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">297</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(401</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,284</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,489</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(104</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,669</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill (September 30, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,250</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">21,099</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,349</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other intangible assets, net (September 30, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,364</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,567</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total assets (September 30, 2015)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">119,939</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63,670</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(327</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">183,282</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Eliminations consist of inter-segment transactions.</td> </tr> </table> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>(b)</b></td> <td valign="top" align="left"> <b><i>Reclassifications</i></b>&#xA0;&#x2013;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders&#x2019; equity.</p> </div> 41947000 2015-12-31 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>(a)</b></td> <td valign="top" align="left"><b><i>Recent Accounting Pronouncements</i></b>&#xA0;&#x2013;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In November 2015, the FASB issued ASU 2015-17,&#xA0;<i>Balance Sheet Classification of Deferred Taxes</i>, which simplifies the financial statement presentation of deferred income taxes by requiring that deferred income tax assets and liabilities be classified as noncurrent within a classified statement of financial position. Adoption and implementation of the guidance is not required by the Company until issuance of fiscal 2018 first quarter financial statements. However, in light of early adoption being permitted and believing the required presentation results in more useful and comparable information related to our net deferred income tax assets, the Company has chosen to adopt the guidance as of December&#xA0;31, 2015 and retrospectively apply the guidance to the prior period presented. This retrospective application results in $3,431 of deferred income tax assets being reclassified from current assets to non-current assets in the September&#xA0;30, 2015 balance sheet included herein. Adoption of this guidance did not have an impact on the Company&#x2019;s consolidated results of operations or cash flows.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Condensed Consolidated Financial Statements.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>2.&#xA0;<u>Significant Accounting Policies</u></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A summary of the Company&#x2019;s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company&#x2019;s fiscal 2015 Annual Report on Form 10-K.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>(a)</b></td> <td valign="top" align="left"><b><i>Recent Accounting Pronouncements</i></b>&#xA0;&#x2013;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In November 2015, the FASB issued ASU 2015-17,&#xA0;<i>Balance Sheet Classification of Deferred Taxes</i>, which simplifies the financial statement presentation of deferred income taxes by requiring that deferred income tax assets and liabilities be classified as noncurrent within a classified statement of financial position. Adoption and implementation of the guidance is not required by the Company until issuance of fiscal 2018 first quarter financial statements. However, in light of early adoption being permitted and believing the required presentation results in more useful and comparable information related to our net deferred income tax assets, the Company has chosen to adopt the guidance as of December&#xA0;31, 2015 and retrospectively apply the guidance to the prior period presented. This retrospective application results in $3,431 of deferred income tax assets being reclassified from current assets to non-current assets in the September&#xA0;30, 2015 balance sheet included herein. Adoption of this guidance did not have an impact on the Company&#x2019;s consolidated results of operations or cash flows.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Condensed Consolidated Financial Statements.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>(b)</b></td> <td valign="top" align="left"> <b><i>Reclassifications</i></b>&#xA0;&#x2013;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders&#x2019; equity.</p> </div> VIVO 0.21 776000 8893000 1391000 1186000 47160000 1611000 8407000 16000 13586000 31583000 96000 113000 600000 8106000 13699000 -787000 17000 58000 4806000 1611000 6443000 3449000 17997000 -1392000 -6937000 3381000 433000 -314000 8173000 388000 15577000 834000 8407000 896000 281000 1470000 0.39 0.29 0.26 2 2 0.18 2 35301000 10330000 71000 11859000 3236000 367000 -438000 20000 115000 91000 8893000 8407000 1391000 1611000 -787000 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-10-01 2015-12-31 0000794172 us-gaap:AdditionalPaidInCapitalMember 2015-10-01 2015-12-31 0000794172 us-gaap:RetainedEarningsMember 2015-10-01 2015-12-31 0000794172 us-gaap:CommonStockMember 2015-10-01 2015-12-31 0000794172 us-gaap:IntersegmentEliminationMember 2015-10-01 2015-12-31 0000794172 us-gaap:MaterialReconcilingItemsMembervivo:LifeScienceMember 2015-10-01 2015-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:LifeScienceMember 2015-10-01 2015-12-31 0000794172 us-gaap:MaterialReconcilingItemsMembervivo:DiagnosticsMember 2015-10-01 2015-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:DiagnosticsMember 2015-10-01 2015-12-31 0000794172 us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticManufacturingCustomersMembervivo:LifeScienceMember 2015-10-01 2015-12-31 0000794172 us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticDistributorCustomersMember 2015-10-01 2015-12-31 0000794172 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticDistributorCustomersMember 2015-10-01 2015-12-31 0000794172 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticDistributorCustomersMember 2015-10-01 2015-12-31 0000794172 us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticDistributorCustomersMembervivo:DiagnosticsMember 2015-10-01 2015-12-31 0000794172 2015-10-01 2015-12-31 0000794172 us-gaap:IntersegmentEliminationMember 2014-10-01 2014-12-31 0000794172 us-gaap:MaterialReconcilingItemsMembervivo:LifeScienceMember 2014-10-01 2014-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:LifeScienceMember 2014-10-01 2014-12-31 0000794172 us-gaap:MaterialReconcilingItemsMembervivo:DiagnosticsMember 2014-10-01 2014-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:DiagnosticsMember 2014-10-01 2014-12-31 0000794172 us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticManufacturingCustomersMembervivo:LifeScienceMember 2014-10-01 2014-12-31 0000794172 us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticDistributorCustomersMember 2014-10-01 2014-12-31 0000794172 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticDistributorCustomersMember 2014-10-01 2014-12-31 0000794172 us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticDistributorCustomersMembervivo:DiagnosticsMember 2014-10-01 2014-12-31 0000794172 2014-10-01 2014-12-31 0000794172 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembervivo:TwoDiagnosticDistributorCustomersMember 2014-10-01 2015-09-30 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-09-30 0000794172 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0000794172 us-gaap:RetainedEarningsMember 2015-09-30 0000794172 us-gaap:CommonStockMember 2015-09-30 0000794172 us-gaap:IntersegmentEliminationMember 2015-09-30 0000794172 us-gaap:OperatingSegmentsMembervivo:LifeScienceMember 2015-09-30 0000794172 us-gaap:OperatingSegmentsMembervivo:DiagnosticsMember 2015-09-30 0000794172 us-gaap:OtherNoncurrentAssetsMember 2015-09-30 0000794172 us-gaap:OtherCurrentAssetsMember 2015-09-30 0000794172 vivo:AccountingStandardsUpdate201517Member 2015-09-30 0000794172 vivo:IllumigeneInstrumentsMember 2015-09-30 0000794172 vivo:KitsAndReagentsMember 2015-09-30 0000794172 vivo:TrademarksLicensesAndPatentsMember 2015-09-30 0000794172 vivo:ManufacturingTechnologiesCoreProductsAndCellLinesMember 2015-09-30 0000794172 vivo:CustomerListsAndSupplyAgreementsMember 2015-09-30 0000794172 2015-09-30 0000794172 2014-09-30 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000794172 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000794172 us-gaap:RetainedEarningsMember 2015-12-31 0000794172 us-gaap:CommonStockMember 2015-12-31 0000794172 us-gaap:IntersegmentEliminationMember 2015-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:LifeScienceMember 2015-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:DiagnosticsMember 2015-12-31 0000794172 us-gaap:OtherNoncurrentAssetsMember 2015-12-31 0000794172 us-gaap:OtherCurrentAssetsMember 2015-12-31 0000794172 vivo:IllumigeneInstrumentsMember 2015-12-31 0000794172 vivo:KitsAndReagentsMember 2015-12-31 0000794172 vivo:TrademarksLicensesAndPatentsMember 2015-12-31 0000794172 vivo:ManufacturingTechnologiesCoreProductsAndCellLinesMember 2015-12-31 0000794172 vivo:CustomerListsAndSupplyAgreementsMember 2015-12-31 0000794172 2015-12-31 0000794172 2014-12-31 0000794172 2016-01-31 shares iso4217:USD iso4217:USD shares pure vivo:Customer EX-101.SCH 6 vivo-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 108 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Cash and Equivalents link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Reportable Segment and Major Customers Information link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Cash and Equivalents (Tables) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Reportable Segment and Major Customers Information (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Inventories - Components of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Reportable Segment and Major Customers Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Reportable Segment and Major Customers Information - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 vivo-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 vivo-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 vivo-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 vivo-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.3.1.900
Document and Entity Information - shares
3 Months Ended
Dec. 31, 2015
Jan. 31, 2016
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Dec. 31, 2015  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
Trading Symbol VIVO  
Entity Registrant Name MERIDIAN BIOSCIENCE INC  
Entity Central Index Key 0000794172  
Current Fiscal Year End Date --09-30  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   42,051,142
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.3.1.900
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Income Statement [Abstract]    
NET REVENUES $ 47,160 $ 48,013
COST OF SALES 15,577 18,776
GROSS PROFIT 31,583 29,237
OPERATING EXPENSES    
Research and development 3,381 3,103
Selling and marketing 6,443 6,080
General and administrative 8,173 7,385
Total operating expenses 17,997 16,568
OPERATING INCOME 13,586 12,669
OTHER INCOME (EXPENSE)    
Interest income 17 6
Other, net 96 (582)
Total other income (expense) 113 (576)
EARNINGS BEFORE INCOME TAXES 13,699 12,093
INCOME TAX PROVISION 4,806 4,192
NET EARNINGS $ 8,893 $ 7,901
BASIC EARNINGS PER COMMON SHARE $ 0.21 $ 0.19
DILUTED EARNINGS PER COMMON SHARE $ 0.21 $ 0.19
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-BASIC 41,947 41,607
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARES AND UNITS 380 334
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-DILUTED 42,327 41,941
ANTI-DILUTIVE SECURITIES:    
Common share options and restricted shares and units 450 566
DIVIDENDS DECLARED PER COMMON SHARE $ 0.20 $ 0.20
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.3.1.900
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Statement of Comprehensive Income [Abstract]    
Net earnings $ 8,893 $ 7,901
Foreign currency translation adjustment (787) (1,365)
COMPREHENSIVE INCOME $ 8,106 $ 6,536
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Dec. 31, 2015
Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES    
Net earnings $ 8,893 $ 7,901
Non-cash items included in net earnings:    
Depreciation of property, plant and equipment 896 927
Amortization of intangible assets 388 469
Amortization of deferred illumigene® instrument costs 281 395
Stock-based compensation 1,611 1,428
Deferred income taxes 433 100
Change in current assets (1,186) 4,878
Change in current liabilities 834 246
Other, net (58) (259)
Net cash provided by operating activities 12,092 16,085
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchases of property, plant and equipment (776) (1,331)
Purchase of equity method investment (600)  
Purchases of intangible assets (16)  
Net cash used for investing activities (1,392) (1,331)
CASH FLOWS FROM FINANCING ACTIVITIES    
Dividends paid (8,407) (8,330)
Proceeds and tax benefits from exercises of stock options 1,470 499
Net cash used for financing activities (6,937) (7,831)
Effect of Exchange Rate Changes on Cash and Equivalents (314) (454)
Net Increase in Cash and Equivalents 3,449 6,469
Cash and Equivalents at Beginning of Period 49,973 43,047
Cash and Equivalents at End of Period $ 53,422 $ 49,516
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.3.1.900
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2015
Sep. 30, 2015
CURRENT ASSETS    
Cash and equivalents $ 53,422 $ 49,973
Accounts receivable, less allowances of $222 and $248 27,617 26,254
Inventories 38,778 35,817
Prepaid expenses and other current assets 3,414 7,378
Total current assets 123,231 119,422
PROPERTY, PLANT AND EQUIPMENT, at Cost    
Land 981 986
Buildings and improvements 30,119 30,056
Machinery, equipment and furniture 42,363 41,541
Construction in progress 938 1,139
Subtotal 74,401 73,722
Less: accumulated depreciation and amortization 46,952 46,230
Net property, plant and equipment 27,449 27,492
OTHER ASSETS    
Goodwill 22,064 22,349
Other intangible assets, net 5,465 5,931
Restricted cash 1,000 1,000
Deferred illumigene instrument costs, net 1,671 1,750
Deferred income taxes 4,566 4,954
Other assets 989 384
Total other assets 35,755 36,368
TOTAL ASSETS 186,435 183,282
CURRENT LIABILITIES    
Accounts payable 7,208 6,646
Accrued employee compensation costs 4,990 5,132
Other accrued expenses 2,601 2,587
Income taxes payable 933 886
Total current liabilities 15,732 15,251
NON-CURRENT LIABILITIES $ 2,129 $ 2,158
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY    
Preferred stock, no par value; 1,000,000 shares authorized; none issued
Common shares, no par value; 71,000,000 shares authorized; 42,044,388 and 41,838,399 shares issued, respectively $ 0 $ 0
Additional paid-in capital 120,153 117,151
Retained earnings 51,538 51,052
Accumulated other comprehensive income (loss) (3,117) (2,330)
Total shareholders' equity 168,574 165,873
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 186,435 $ 183,282
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2015
Sep. 30, 2015
Statement of Financial Position [Abstract]    
Allowances for accounts receivable $ 222 $ 248
Preferred stock, par value
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Common stock, par value
Common stock, shares authorized 71,000,000 71,000,000
Common stock, shares issued 42,044,388 41,838,399
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.3.1.900
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - 3 months ended Dec. 31, 2015 - USD ($)
shares in Thousands, $ in Thousands
Total
Common Shares Issued [Member]
Additional Paid-In Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Sep. 30, 2015 $ 165,873   $ 117,151 $ 51,052 $ (2,330)
Beginning balance, Shares at Sep. 30, 2015   41,838      
Cash dividends paid (8,407)     (8,407)  
Exercise of stock options 1,391   1,391    
Exercise of stock options, Shares   91      
Conversion of restricted stock units   115      
Stock compensation expense 1,611   1,611    
Net earnings 8,893     8,893  
Foreign currency translation adjustment (787)       (787)
Ending balance at Dec. 31, 2015 $ 168,574   $ 120,153 $ 51,538 $ (3,117)
Ending balance, Shares at Dec. 31, 2015   42,044      
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.3.1.900
Basis of Presentation
3 Months Ended
Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation

1. Basis of Presentation

The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of December 31, 2015, the results of its operations for the three month periods ended December 31, 2015 and 2014, and its cash flows for the three month periods ended December 31, 2015 and 2014. These statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s fiscal 2015 Annual Report on Form 10-K. Financial information as of September 30, 2015 has been derived from the Company’s audited consolidated financial statements. The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.3.1.900
Significant Accounting Policies
3 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Significant Accounting Policies

2. Significant Accounting Policies

A summary of the Company’s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company’s fiscal 2015 Annual Report on Form 10-K.

 

(a) Recent Accounting Pronouncements –

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which simplifies the financial statement presentation of deferred income taxes by requiring that deferred income tax assets and liabilities be classified as noncurrent within a classified statement of financial position. Adoption and implementation of the guidance is not required by the Company until issuance of fiscal 2018 first quarter financial statements. However, in light of early adoption being permitted and believing the required presentation results in more useful and comparable information related to our net deferred income tax assets, the Company has chosen to adopt the guidance as of December 31, 2015 and retrospectively apply the guidance to the prior period presented. This retrospective application results in $3,431 of deferred income tax assets being reclassified from current assets to non-current assets in the September 30, 2015 balance sheet included herein. Adoption of this guidance did not have an impact on the Company’s consolidated results of operations or cash flows.

Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Condensed Consolidated Financial Statements.

 

(b) Reclassifications –

Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.3.1.900
Cash and Equivalents
3 Months Ended
Dec. 31, 2015
Cash and Cash Equivalents [Abstract]  
Cash and Equivalents

3. Cash and Equivalents

Cash and equivalents include the following components:

 

     December 31, 2015      September 30, 2015  
     Cash and
Equivalents
     Other
Assets
     Cash and
Equivalents
     Other
Assets
 

Overnight repurchase agreements

   $ 25,147      $ —        $ 25,436      $ —    

Cash on hand—

           

Restricted

     —          1,000        —          1,000  

Unrestricted

     28,275        —          24,537        —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 53,422      $ 1,000      $ 49,973      $ 1,000  
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.3.1.900
Inventories
3 Months Ended
Dec. 31, 2015
Inventory Disclosure [Abstract]  
Inventories

4. Inventories

Inventories are comprised of the following:

 

     December 31,
2015
     September 30,
2015
 

Raw materials

   $ 7,351      $ 7,095  

Work-in-process

     12,297        10,096  

Finished goods—illumigene instruments

     2,260        1,890  

Finished goods—kits and reagents

     16,870        16,736  
  

 

 

    

 

 

 

Total

   $ 38,778      $ 35,817  
  

 

 

    

 

 

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.3.1.900
Reportable Segment and Major Customers Information
3 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Reportable Segment and Major Customers Information

5. Reportable Segment and Major Customers Information

Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Our reportable segments are Diagnostics and Life Science, both of which are headquartered in Cincinnati, Ohio, which also serves as the Diagnostics segment’s base of manufacturing operations and research and development. The Diagnostics segment has sales and distribution facilities in the United States, Europe and Australia. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China to further pursue growing revenue opportunities in Asia.

Amounts due from two Diagnostics distributor customers accounted for 26% and 21% of consolidated accounts receivable at December 31, 2015 and September 30, 2015, respectively. Revenues from these two distributor customers accounted for 39% and 41% of the Diagnostics segment third-party revenues during the three months ended December 31, 2015 and 2014, respectively; and represented 29% and 31% of consolidated revenues for the fiscal 2016 and 2015 first quarters, respectively.

 

Within our Life Science segment, two diagnostic manufacturing customers accounted for 18% of the segment’s third-party revenues during each of the three months ended December 31, 2015 and 2014.

Segment information for the interim periods is as follows:

 

     Diagnostics      Life Science      Eliminations(1)      Total  

Three Months Ended December 31, 2015

  

Net revenues—

           

Third-party

   $ 35,301      $ 11,859      $ —        $ 47,160  

Inter-segment

     71        367        (438      —    

Operating income

     10,330        3,236        20        13,586  

Goodwill (December 31, 2015)

     1,250        20,814        —          22,064  

Other intangible assets, net (December 31, 2015)

     2,236        3,229        —          5,465  

Total assets (December 31, 2015)

     120,780        65,927        (272      186,435  

Three Months Ended December 31, 2014

           

Net revenues—

           

Third-party

   $ 36,586      $ 11,427      $ —        $ 48,013  

Inter-segment

     104        297        (401      —    

Operating income

     10,284        2,489        (104      12,669  

Goodwill (September 30, 2015)

     1,250        21,099        —          22,349  

Other intangible assets, net (September 30, 2015)

     2,364        3,567        —          5,931  

Total assets (September 30, 2015)

     119,939        63,670        (327      183,282  

 

(1) Eliminations consist of inter-segment transactions.

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets
3 Months Ended
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

6. Intangible Assets

A summary of our acquired intangible assets subject to amortization, as of December 31, 2015 and September 30, 2015 is as follows:

 

     December 31, 2015      September 30, 2015  
     Gross
Carrying
Value
     Accumulated
Amortization
     Gross
Carrying
Value
     Accumulated
Amortization
 

Manufacturing technologies, core products and cell lines

   $ 11,547      $ 10,963      $ 11,582      $ 10,906  

Trademarks, licenses and patents

     6,349        3,450        6,410        3,296  

Customer lists and supply agreements

     12,012        10,030        12,105        9,964  
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 29,908      $ 24,443      $ 30,097      $ 24,166  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

The actual aggregate amortization expense for these intangible assets was $388 and $469 for the three months ended December 31, 2015 and 2014, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2021 is as follows: remainder of fiscal 2016 – $1,009, fiscal 2017 – $1,106, fiscal 2018 – $1,085, fiscal 2019 – $1,045, fiscal 2020 – $873 and fiscal 2021 – $313.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.3.1.900
Significant Accounting Policies (Policies)
3 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Recent Accounting Pronouncements
(a) Recent Accounting Pronouncements –

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which simplifies the financial statement presentation of deferred income taxes by requiring that deferred income tax assets and liabilities be classified as noncurrent within a classified statement of financial position. Adoption and implementation of the guidance is not required by the Company until issuance of fiscal 2018 first quarter financial statements. However, in light of early adoption being permitted and believing the required presentation results in more useful and comparable information related to our net deferred income tax assets, the Company has chosen to adopt the guidance as of December 31, 2015 and retrospectively apply the guidance to the prior period presented. This retrospective application results in $3,431 of deferred income tax assets being reclassified from current assets to non-current assets in the September 30, 2015 balance sheet included herein. Adoption of this guidance did not have an impact on the Company’s consolidated results of operations or cash flows.

Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Condensed Consolidated Financial Statements.

Reclassifications
(b) Reclassifications –

Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.3.1.900
Cash and Equivalents (Tables)
3 Months Ended
Dec. 31, 2015
Cash and Cash Equivalents [Abstract]  
Components of Cash and Cash Equivalents

Cash and equivalents include the following components:

 

     December 31, 2015      September 30, 2015  
     Cash and
Equivalents
     Other
Assets
     Cash and
Equivalents
     Other
Assets
 

Overnight repurchase agreements

   $ 25,147      $ —        $ 25,436      $ —    

Cash on hand—

           

Restricted

     —          1,000        —          1,000  

Unrestricted

     28,275        —          24,537        —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 53,422      $ 1,000      $ 49,973      $ 1,000  
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.3.1.900
Inventories (Tables)
3 Months Ended
Dec. 31, 2015
Inventory Disclosure [Abstract]  
Components of Inventories

Inventories are comprised of the following:

 

     December 31,
2015
     September 30,
2015
 

Raw materials

   $ 7,351      $ 7,095  

Work-in-process

     12,297        10,096  

Finished goods—illumigene instruments

     2,260        1,890  

Finished goods—kits and reagents

     16,870        16,736  
  

 

 

    

 

 

 

Total

   $ 38,778      $ 35,817  
  

 

 

    

 

 

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.3.1.900
Reportable Segment and Major Customers Information (Tables)
3 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Segment Information

Segment information for the interim periods is as follows:

 

     Diagnostics      Life Science      Eliminations(1)      Total  

Three Months Ended December 31, 2015

  

Net revenues—

           

Third-party

   $ 35,301      $ 11,859      $ —        $ 47,160  

Inter-segment

     71        367        (438      —    

Operating income

     10,330        3,236        20        13,586  

Goodwill (December 31, 2015)

     1,250        20,814        —          22,064  

Other intangible assets, net (December 31, 2015)

     2,236        3,229        —          5,465  

Total assets (December 31, 2015)

     120,780        65,927        (272      186,435  

Three Months Ended December 31, 2014

           

Net revenues—

           

Third-party

   $ 36,586      $ 11,427      $ —        $ 48,013  

Inter-segment

     104        297        (401      —    

Operating income

     10,284        2,489        (104      12,669  

Goodwill (September 30, 2015)

     1,250        21,099        —          22,349  

Other intangible assets, net (September 30, 2015)

     2,364        3,567        —          5,931  

Total assets (September 30, 2015)

     119,939        63,670        (327      183,282  

 

(1) Eliminations consist of inter-segment transactions.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets (Tables)
3 Months Ended
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of Acquired Intangible Assets Subject to Amortization

A summary of our acquired intangible assets subject to amortization, as of December 31, 2015 and September 30, 2015 is as follows:

 

     December 31, 2015      September 30, 2015  
     Gross
Carrying
Value
     Accumulated
Amortization
     Gross
Carrying
Value
     Accumulated
Amortization
 

Manufacturing technologies, core products and cell lines

   $ 11,547      $ 10,963      $ 11,582      $ 10,906  

Trademarks, licenses and patents

     6,349        3,450        6,410        3,296  

Customer lists and supply agreements

     12,012        10,030        12,105        9,964  
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 29,908      $ 24,443      $ 30,097      $ 24,166  
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.3.1.900
Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Sep. 30, 2015
Schedule Of Accounting Policies [Line Items]    
Deferred income taxes $ 4,566 $ 4,954
ASU 2015-17 [Member]    
Schedule Of Accounting Policies [Line Items]    
Deferred income taxes   $ 3,431
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.3.1.900
Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Sep. 30, 2015
Dec. 31, 2014
Sep. 30, 2014
Cash and Cash Equivalents [Line Items]        
Cash on hand - Restricted $ 1,000 $ 1,000    
Total 53,422 49,973 $ 49,516 $ 43,047
Cash and Equivalents [Member]        
Cash and Cash Equivalents [Line Items]        
Overnight repurchase agreements 25,147 25,436    
Cash on hand - Unrestricted 28,275 24,537    
Total 53,422 49,973    
Other Assets [Member]        
Cash and Cash Equivalents [Line Items]        
Cash on hand - Restricted 1,000 1,000    
Total $ 1,000 $ 1,000    
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.3.1.900
Inventories - Components of Inventories (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Sep. 30, 2015
Inventory [Line Items]    
Raw materials $ 7,351 $ 7,095
Work-in-process 12,297 10,096
Total 38,778 35,817
Illumigene Instruments [Member]    
Inventory [Line Items]    
Finished goods 2,260 1,890
Kits and Reagents [Member]    
Inventory [Line Items]    
Finished goods $ 16,870 $ 16,736
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.3.1.900
Reportable Segment and Major Customers Information - Additional Information (Detail) - Customer Concentration Risk [Member] - Customer
3 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Sep. 30, 2015
Two Diagnostic Distributor Customers [Member] | Consolidated Accounts Receivable [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Number of major customers 2   2
Concentration risk percentage 26.00%   21.00%
Two Diagnostic Distributor Customers [Member] | Segment, Third-Party Sales Revenue [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Number of major customers 2 2  
Two Diagnostic Distributor Customers [Member] | Segment, Third-Party Sales Revenue [Member] | Diagnostics [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Concentration risk percentage 39.00% 41.00%  
Two Diagnostic Distributor Customers [Member] | Revenues [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Concentration risk percentage 29.00% 31.00%  
Two Diagnostic Manufacturing Customers [Member] | Segment, Third-Party Sales Revenue [Member] | Life Science [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Number of major customers 2 2  
Concentration risk percentage 18.00% 18.00%  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.3.1.900
Reportable Segment and Major Customers Information - Segment Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Sep. 30, 2015
Segment Reporting Information [Line Items]      
NET REVENUES $ 47,160 $ 48,013  
Operating income 13,586 12,669  
Goodwill 22,064   $ 22,349
Other intangible assets, net 5,465   5,931
Total assets 186,435   183,282
Inter-segment [Member] | Diagnostics [Member]      
Segment Reporting Information [Line Items]      
NET REVENUES 71 104  
Inter-segment [Member] | Life Science [Member]      
Segment Reporting Information [Line Items]      
NET REVENUES 367 297  
Eliminations [Member]      
Segment Reporting Information [Line Items]      
NET REVENUES (438) (401)  
Operating income 20 (104)  
Total assets (272)   (327)
Operating Segments [Member] | Diagnostics [Member]      
Segment Reporting Information [Line Items]      
NET REVENUES 35,301 36,586  
Operating income 10,330 10,284  
Goodwill 1,250   1,250
Other intangible assets, net 2,236   2,364
Total assets 120,780   119,939
Operating Segments [Member] | Life Science [Member]      
Segment Reporting Information [Line Items]      
NET REVENUES 11,859 11,427  
Operating income 3,236 $ 2,489  
Goodwill 20,814   21,099
Other intangible assets, net 3,229   3,567
Total assets $ 65,927   $ 63,670
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Sep. 30, 2015
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 29,908 $ 30,097
Accumulated Amortization 24,443 24,166
Manufacturing Technologies, Core Products and Cell Lines [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 11,547 11,582
Accumulated Amortization 10,963 10,906
Trademarks, Licenses and Patents [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 6,349 6,410
Accumulated Amortization 3,450 3,296
Customer Lists and Supply Agreements [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 12,012 12,105
Accumulated Amortization $ 10,030 $ 9,964
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of intangible assets $ 388 $ 469
Estimated amortization expense for intangible assets remainder of fiscal year 2016 1,009  
2017 1,106  
2018 1,085  
2019 1,045  
2020 873  
2021 $ 313  
EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 37 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 38 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 60 126 1 false 23 0 false 5 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.meridianbioscience.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfIncome Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfOtherComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 108 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statements 7 false false R8.htm 109 - Disclosure - Basis of Presentation Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation Notes 8 false false R9.htm 110 - Disclosure - Significant Accounting Policies Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Significant Accounting Policies Notes 9 false false R10.htm 111 - Disclosure - Cash and Equivalents Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock Cash and Equivalents Notes 10 false false R11.htm 112 - Disclosure - Inventories Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories Notes 11 false false R12.htm 113 - Disclosure - Reportable Segment and Major Customers Information Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Reportable Segment and Major Customers Information Notes 12 false false R13.htm 114 - Disclosure - Intangible Assets Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets Notes 13 false false R14.htm 115 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Significant Accounting Policies (Policies) Policies http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 14 false false R15.htm 116 - Disclosure - Cash and Equivalents (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlockTables Cash and Equivalents (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock 15 false false R16.htm 117 - Disclosure - Inventories (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventories (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock 16 false false R17.htm 118 - Disclosure - Reportable Segment and Major Customers Information (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Reportable Segment and Major Customers Information (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 17 false false R18.htm 119 - Disclosure - Intangible Assets (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 18 false false R19.htm 120 - Disclosure - Significant Accounting Policies - Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation Significant Accounting Policies - Additional Information (Detail) Details 19 false false R20.htm 121 - Disclosure - Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureCashAndEquivalentsComponentsOfCashAndCashEquivalents Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) Details 20 false false R21.htm 122 - Disclosure - Inventories - Components of Inventories (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureInventoriesComponentsOfInventories Inventories - Components of Inventories (Detail) Details 21 false false R22.htm 123 - Disclosure - Reportable Segment and Major Customers Information - Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureReportableSegmentAndMajorCustomersInformationAdditionalInformation Reportable Segment and Major Customers Information - Additional Information (Detail) Details 22 false false R23.htm 124 - Disclosure - Reportable Segment and Major Customers Information - Segment Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureReportableSegmentAndMajorCustomersInformationSegmentInformation Reportable Segment and Major Customers Information - Segment Information (Detail) Details 23 false false R24.htm 125 - Disclosure - Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureIntangibleAssetsSummaryOfAcquiredIntangibleAssetsSubjectToAmortization Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) Details 24 false false R25.htm 126 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) Details 25 false false All Reports Book All Reports vivo-20151231.xml vivo-20151231.xsd vivo-20151231_cal.xml vivo-20151231_def.xml vivo-20151231_lab.xml vivo-20151231_pre.xml true true ZIP 42 0001193125-16-454772-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-454772-xbrl.zip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�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�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� =FEV;RTR,#$U,3(S,2YX&UL M4$L! A0#% @ $T=)2)=H]O<>#P 1=( !4 ( !7%D M '9I=F\M,C Q-3$R,S%?9&5F+GAM;%!+ 0(4 Q0 ( !-'24@LR7)."3T M $KO @ 5 " :UH !V:79O+3(P,34Q,C,Q7VQA8BYX;6Q0 M2P$"% ,4 " 31TE(\\8GD)L< #"]@$ %0 @ 'II0 K=FEV;RTR,#$U,3(S,5]P&UL4$L%!@ & 8 B@$ +?" $! end